Farther Finance Advisors LLC Buys 14,431 Shares of Johnson & Johnson (NYSE:JNJ)

Farther Finance Advisors LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 27.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 66,328 shares of the company's stock after purchasing an additional 14,431 shares during the period. Farther Finance Advisors LLC's holdings in Johnson & Johnson were worth $10,165,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. WealthTrak Capital Management LLC acquired a new position in Johnson & Johnson during the fourth quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. bought a new stake in Johnson & Johnson in the 4th quarter valued at approximately $29,000. Conquis Financial LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at approximately $33,000. Bernard Wealth Management Corp. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $36,000. Finally, Runnymede Capital Advisors Inc. bought a new position in shares of Johnson & Johnson in the fourth quarter valued at $38,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 0.8%

JNJ stock traded down $1.26 during mid-day trading on Wednesday, reaching $155.19. The company's stock had a trading volume of 6,007,883 shares, compared to its average volume of 7,945,129. The company has a market cap of $373.41 billion, a price-to-earnings ratio of 23.34, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The business's 50 day moving average price is $153.52 and its 200 day moving average price is $153.69. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. On average, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.35%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is 57.84%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Wall Street Zen downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Bank of America decreased their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research note on Thursday, April 10th. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Raymond James dropped their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.